TrialJectory

OverviewSuggest Edit

TrialJectory is a company that develops an AI-based healthcare platform created to connect cancer patients with the right clinical trial. It is an AI-based trial matching platform that uses self-reported clinical information to facilitate clinical trial search, matching, and enrollment by cancer patients and their physicians. The company aims to provide access to more advanced care in clinics.
TypePrivate
Founded2017
HQNew York, NY, US
Websitetrialjectory.com

Latest Updates

Employees (est.) (Sept 2021)20
Cybersecurity ratingAMore

Key People/Management at TrialJectory

Tzvia Bader

Tzvia Bader

CEO and Co-Founder
Guy Gildor

Guy Gildor

CTO
Show more

TrialJectory Office Locations

TrialJectory has an office in New York
New York, NY, US (HQ)
119 W 24th St
Show all (1)

TrialJectory Financials and Metrics

Summary Metrics

Founding Date

2017

TrialJectory total Funding

$2.7 m

TrialJectory latest funding size

$2.7 m

Time since last funding

2 years ago

TrialJectory investors

TrialJectory's latest funding round in December 2019 was reported to be $2.7 m. In total, TrialJectory has raised $2.7 m
Show all financial metrics

TrialJectory Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

TrialJectory Online and Social Media Presence

Embed Graph

TrialJectory News and Updates

TrialJectory Survey Reveals 66 Percent of Cancer Patients Desire Greater Involvement in Treatment Decisions as a Result of COVID-19

NEW YORK, June 7, 2021 /PRNewswire/ -- TrialJectory ("the Company''), an AI-powered digital health platform that empowers cancer patients to find advanced new treatment options and enables the pharmaceutical industry to effectively design and recruit for clinical trials, announced today...

TrialJectory Appoints former Deputy Chief Medical Officer for the American Cancer Society, Dr. J. Leonard Lichtenfeld to Clinical Advisory Board

NEW YORK, Nov. 10, 2020 /PRNewswire/ -- TrialJectory ("the Company"), an AI-powered digital health platform that empowers cancer patients to find advanced new treatment options that fit their precise profile, announced today that it has appointed Dr. J. Leonard Lichtenfeld, MD, MACP, to...

TrialJectory Blogs

Take back control

I have been thinking a lot about Control lately. How the second you get diagnosed you lose control over your life.   It doesn't matter if you are a control freak or not - we now lost control. We are not sure how we’re going to feel tomorrow morning, we’re not sure about what’s going to [...] The pos…

CAR T Cell Therapy Talk

Did you miss Dr. Joshua Mansour’s webinar? You can view it anytime here.    Dr. Joshua Mansour is a board certified hematologist and oncologist  with additional training at Stanford in cell therapy and bone marrow transplantation. In our talk, he focuses on the innovations and progress in CAR T cell…

Myelofibrosis News

Latest News in MF Cancer Research   Myelofibrosis (MF) is a rare type of bone marrow cancer that disrupts normal production of blood cells. MF usually develops slowly, and initially a patient may not notice any symptoms, but over time patients begin to experience fatigue as a result of anemia (low r…

TrialJectory 2020 Review: A Big Step Towards Cancer Patient Empowerment

2020 has been a difficult year for all of us. At times, we have been completely overwhelmed by the COVID-19 pandemic, but throughout, we have persevered to make a difference in the lives of patients suffering from cancer. There is something about a cancer diagnosis that is paralyzing, resulting in l…

Health Decisions, OncoBay Clinical, and TrialJectory Partner to Provide Specialized Clinical Development Services in Women’s Oncology

Durham, N.C., and Tampa, Fla., December 1, 2020 – Health Decisions, Inc., a full-service contract research organization (CRO) specializing in women’s health clinical research and diagnostic and medical device development, and OncoBay Clinical, Inc., a full-service boutique CRO specializing in comple…

TIME Selects TrialJectory’s AI-Powered, Clinical Trial-Matching Platform for ‘100 Best Inventions of 2020’ List

Annual List Highlights Groundbreaking Inventions that Change How We Live and Make the World a Better Place   NEW YORK, Nov. 20, 2020 -- TrialJectory ("the Company"), an AI-powered digital health platform that empowers cancer patients to find advanced new treatment options that fit their precise prof…
Show more

TrialJectory Frequently Asked Questions

  • When was TrialJectory founded?

    TrialJectory was founded in 2017.

  • Who are TrialJectory key executives?

    TrialJectory's key executives are Tzvia Bader and Guy Gildor.

  • How many employees does TrialJectory have?

    TrialJectory has 20 employees.

  • Who are TrialJectory competitors?

    Competitors of TrialJectory include Vara, xCures and Vine Health.

  • Where is TrialJectory headquarters?

    TrialJectory headquarters is located at 119 W 24th St, New York.

  • Where are TrialJectory offices?

    TrialJectory has an office in New York.

  • How many offices does TrialJectory have?

    TrialJectory has 1 office.